[1]
Maniakas A, Davies L, Zafereo ME. Thyroid disease around the World. Otolaryngol Clin North Am 2018; 51(3): 631-42.
[2]
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 2017; 317(13): 1338-48.
[3]
Wells SA, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: An update. J Clin Endocrinol Metab 2013; 98(8): 3149-64.
[4]
Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 2015; 8(1): 30-40.
[5]
Davicioni E, Haddad Z. Thyroid cancer diagnostics. US9994907 . (2018).
[6]
Hahn MA, Yim JH, Fong Y, Li XA, Wu X. Methods, treatment, and compositions for characterizing thyroid nodule . US15217645 . 2017.
[7]
Wei W-J, Shen C-T, Song H-J, Qiu Z-L, Luo Q-Y. MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2016; 84(1): 127-33.
[8]
De la Chapelle A, Eisfeild AK. Methods and compositions using MIR-3151 in the diagnosis and treatment of thyroid cancer. US9708612. (2017).
[9]
Keller A, Meese E, Borries A, Staehler F, Beier M. miRNA fingerprint in the diagnosis of diseases. US9702008 . (2017).
[10]
Yanai GL, Meiri E, Spector Y, Benjamin H, Dromi N. miRNA expression signature in the classification of thyroid tumors. US9708667 . (2017).
[11]
Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: Diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22(6): 955-69.
[12]
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016; 126(3): 1052-66.
[13]
Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008; 41(4): 278-86.
[14]
Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22(29): 4578-80.
[15]
Yoo S-K, Lee S, Kim S-J, Jee H-G, Kim B-A, Cho H, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. PLoS Genet 2016; 12(8)e1006239
[16]
Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017; 235(2): R43-61.
[17]
Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, et al. RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001; 86(7): 3211-6.
[18]
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91(8): 2892-9.
[19]
Jin Y, Van Nostrand D, Cheng L, Liu M, Chen L. Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol 2018; 125: 111-20.
[20]
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107(9): 2134-42.
[21]
Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind Phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 2012; 30(2): 134-41.
[22]
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31(29): 3639-46.
[23]
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, Phase 3 trial. Lancet Lond Engl 2014; 384(9940): 319-28.
[24]
Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 2014; 6(6): 267-79.
[25]
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372(7): 621-30.
[26]
Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016; 42: 47-55.
[27]
De Falco V, Carlomagno F, Li H-Y, Santoro M. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017; 31(3): 307-18.
[28]
Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, et al. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Best Pract Res Clin Endocrinol Metab 2017; 31(3): 319-34.
[29]
Lange AM, Lo H-W. Inhibiting TRK proteins in clinical cancer therapy. Cancers 2018; 10(4)E105
[30]
Stull RA, Saunders L, Dylla S, et al. Anti-DLL3 antibody drug conjugates and methods of use. US9937268 . (2018).
[31]
Stull RA, Saunders L, Dylla SJ, et al. Methods of delivering DLL3 antibody drug conjugates. US9878053 . (2018).
[32]
Miliotou AN, Papadopoulou LC. CAR T-cell therapy: A new era in cancer immunotherapy. Curr Pharm Biotechnol 2018; 19(1): 5-18.
[33]
Xiao L, Wu Z, Pu C, Cao Z, Sun H, Bi M. Use of chimeric antigen receptor modified cells to treat cancer. US9932405 . (2018).
[34]
Spee PJL, Padkaer SB. Anti-NKG2A antibodies and uses thereof. US9683041 . (2017).
[35]
Chave G, Dayde-Cazals B, Fauvel B, Bories C, Yasri A. Azaindole derivates as multi kinase inhibitors. US9550772 . (2017).
[36]
Pacini F. Which patient with thyroid cancer deserves systemic therapy and when? Best Pract Res Clin Endocrinol Metab 2017; 31(3): 291-4.
[37]
Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the Phase III SELECT trial. J Clin Oncol 2017; 35(23): 2692-9.
[38]
Funahashi Y, Kadowaki T, Matsui J, Simon JS, Xu L. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compound. US9945862 . (2018).
[39]
Liu J-W, Chen C, Loh E-W, Chu C-C, Wang M-Y, Ouyang H-J, et al. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2018; 34(5): 795-803.
[40]
Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, et al. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev 2018; 66: 64-73.
[41]
Santoni M, Guerra F, Conti A, Lucarelli A, Rinaldi S, Belvederesi L, et al. Incidence and risk of cardiotoxicity in cancer patients treated with _targeted therapies. Cancer Treat Rev 2017; 59: 123-31.
[42]
Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis. PLoS One 2012; 7(2) e30353
[43]
Moslehi JJ. Cardiovascular toxic effects of _targeted cancer therapies. N Engl J Med 2016; 375(15): 1457-67.
[44]
Zhang J, Yang PL, Gray NS. _targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9(1): 28-39.
[45]
Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two--_targeted therapies. Eur J Cancer Oxf Engl 2014; 50(12): 2020-36.
[46]
Agrawal VR, Jodon G, Mushtaq R, Bowles DW. Update on multikinase inhibitor therapy for differentiated thyroid cancer. Drugs Today 2018; 54(9): 535-45.
[48]
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12): 2298-308.
[49]
Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, et al. Cabozantinib in thyroid cancer. Recent Patents Anticancer Drug Discov 2015; 10(3): 259-69.
[51]
Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: A focus on cabozantinib. Cancer Manag Res 2015; 7: 265-78.
[52]
Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. Vandetanib for the treatment of medullary thyroid carcinoma. Ann Pharmacother 2014; 48(3): 387-94.
[53]
Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther 2015; 9: 3459-70.
[54]
Johansson S, Read J, Oliver S, Steinberg M, Li Y, Lisbon E, et al. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. Clin Pharmacokinet 2014; 53(9): 837-47.
[55]
Martin P, Oliver S, Robertson J, Kennedy S-J, Read J, Duvauchelle T. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D 2011; 11(1): 37-51.
[56]
Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 2015; 21(21): 4801-10.
[57]
Krajewska J, Kukulska A, Jarzab B. Drug safety evaluation of lenvatinib for thyroid cancer. Expert Opin Drug Saf 2015; 14(12): 1935-43.
[58]
Zhu C, Ma X, Hu Y, Guo L, Chen B, Shen K, et al. Safety and efficacy profile of lenvatinib in cancer therapy: A systematic review and meta-analysis. Onco_target 2016; 7(28): 44545-57.
[60]
Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A Phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid Off J Am Thyroid Assoc 2014; 24(10): 1508-14.
[61]
Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, et al. Overall survival analysis of EXAM, a Phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol Off J Eur Soc Med Oncol 2017; 28(11): 2813-9.
[62]
Tsang VHM, Robinson BG, Learoyd DL. The safety of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Saf 2016; 15(8): 1107-13.
[63]
Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, Phase 2 trial. Lancet Oncol 2012; 13(9): 897-905.
[64]
Sidaway P. Thyroid cancer: Cabozantinib effective in selected patients. Nat Rev Clin Oncol 2017; 14(12): 712.
69
8